There are currently 15 clinical trials in San Bernardino, California looking for participants to engage in research studies. Trials are conducted at various facilities, including San Bernardino Urological Associates. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis
Recruiting
This is a Pre-IDE, prospective, multicenter, randomized, parallel-group, double-blind, vehicle- controlled study to evaluate safety and effectiveness of Nail Genesis DLSO Product for the treatment of DLSO compared with vehicle in infected great toenails in a total of 338 males and non-pregnant, non-lactating, females between 18 and 65 years of age (inclusive). Subjects will be randomized in a 2:1 ratio to receive either Nail Genesis DLSO Product or vehicle. Subject eligibility will be determine... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
12/06/2023
Locations: Metro Clinical Trials, San Bernardino, California
Conditions: Distal Lateral Subungual Onychomycosis, Onychomycosis
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
Recruiting
This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who are at high risk for complications after RSV infection.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: CRMD Research LLC, San Bernardino, California
Conditions: RSV Infection
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Recruiting
To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects unselected for deoxyribonucleic acid (DNA) damage repair deficiencies (DRD) status (Cohort 1) to evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of rPFS in mCRPC subjects harboring DRD (Cohort 2).
Gender:
Male
Ages:
18 years and above
Trial Updated:
07/28/2022
Locations: San Bernardino Urological Associates Medical Group, San Bernardino, California
Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)